Podcasts about wegovy

Episode 1809 - brought to you by our incredible sponsors: True Classic- TrueClassic.com/HARDFACTOR to try them out for yourself. Hydrow- Go to Hydrow.com and use code HARDFACTOR to save up to $450 off your Hydrow Pro Rower! DaftKings- Download the DraftKings Casino app, sign up with code HARDFACTOR, and spin your favorite slots! The Crown is Yours - Gambling problem? Call one eight hundred GAMBLER Lucy- Let's level up your nicotine routine with Lucy.  Go to ⁠⁠Lucy.co/HARDFACTOR⁠⁠ and use promo code (HARDFACTOR) to get 20% off your first order. Must be of age-verified. Better Help - Our listeners get 10% off their first month of online therapy at BetterHelp dot com slash HARDFACTOR Timestamps: 00:00:00 Timestamps 00:04:10 Happy birthday to Wes' Mom 00:05:50 Costco to begin selling Ozempic and Wegovy for half off 00:18:15 Scientists release a report that humans have a lot of alien DNA thanks to abductions 00:24:15 Good old-fashioned cigarette smuggling drone operation in Lithuania  00:28:20 Recall on Canadian thc pouch products Chillows for having way more mgs than advertised 00:32:15 20k bounty placed on man accused of cutting off sea lion's head in front of daughter  Thank you for listening!! If you're still reading, join our community at patreon.com/hardfactor to get access to bonus podcasts, discord chat, and much more... but Most importantly: HAGFD!! Learn more about your ad choices. Visit megaphone.fm/adchoices

 Headlines: – Welcome to Mo News (02:00) – Judge Declines to Stop Guard Troops From Deploying in Illinois, for Now (04:00) – Bari Weiss Named Editor In Chief Of CBS News (12:45) – Day Seven Of The Government Shutdown (19:15) – White House Avoids Setting Deadline For Gaza Talks, But Says It Wants Deal ‘Quickly' (23:50) – Hostage Families Urge Nobel Committee To Give Trump Peace Prize (26:450 – Survey: Most Jewish Americans Say Antisemitism Now Part Of Daily Life (27:15) – Supreme Court Rejects Appeal From Ghislaine Maxwell (28:30) – Costco to Sell Popular Weight-Loss Drugs Ozempic and Wegovy (30:50) – Online Holiday Spending Growth Set To Slow To 5.3% As Shoppers Seek Discounts (32:00) – On This Day In History (33:10) Thanks To Our Sponsors:  – ⁠LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Leesa – 25% off mattress, plus extra $50 off | Promo Code: MONEWS – Factor Meals – 50% your first box plus free shipping | Promo Code: monews50off – Monarch Money - 50% off your first year | Promo Code: MONEWS

SUPPORT OUR WORK: OTPLinks.com

Group Chat News is back with the hottest stories of the week including the government shutdown, Diddy gets sentenced to 4 years in prison, Costco will now sell Ozempic and Wegovy at a discounted price, and Bronny may be the next golf superstar. 

GLP-1s — Ozempic, Wegovy, Mounjaro — they are everywhere right now. Your group chat's talking about them, they're all over TikTok, and maybe even your doctor's mentioned them. You've probably heard that they help with weight loss or that they ‘quiet food noise' — but what's really going on inside your body when you're on these meds? And more importantly what should we, as women, actually know when it comes to our hormones, metabolism, and long-term health? Because let's be real our bodies are not one-size-fits-all, and wellness isn't just about shrinking down a size. So today, we're getting into the real talk: what GLP-1s do, the benefits, the downsides, and how nutrition still plays a major role — whether you're on them, thinking about them, or just trying to make sense of all the hype. Listen up!  The Flourish Heights Podcast was made for women, by women. To be empowered in health starts with a true connection with your body. Join Valerie Agyeman, Women's Health Dietitian as she breaks through topics surrounding periods, women's nutrition, body awareness, and self-care.  Stay Connected: A research review on GLP-1's: https://pmc.ncbi.nlm.nih.gov/articles/PMC10972401/ Follow us on social media: Instagram: @flourishheights / @valerieagyeman / Women's Health Hub: @flourishvulva Is there a topic you'd like covered on the podcast? Submit it to hello@flourishheights.com Say hello! Email us at hello@flourishheights.com Subscribe to our quarterly newsletters: Flourish Heights Newsletter Visit our website: www.flourishheights.com Want to support this podcast? Leave a rating, write a review and share! Thank you!

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________This isn't medical advice — always talk to your doctor before making any health decisions.Join us for an eye-opening conversation with Dr. Komal Patil-Sisodia, MD, a board-certified endocrinologist and obesity medicine specialist, as we uncover why healthcare access is so broken for patients seeking GLP-1 treatments and women's health support. From insurance denials to systemic inequities, Dr. Patil-Sisodia breaks down where the system fails—and how it could change for the better. We're also joined by Sabina, founder of GLP Winner, who shares her personal journey with obesity and her mission to help others find reliable information and providers for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.Community Guest: Sabina | https://www.glpwinner.com/ - Helps compare GLP-1 provider options with transparent pricing, sourcing, and reviews.https://www.tiktok.com/@lawliepophttps://www.instagram.com/lawliepops/https://www.youtube.com/@lawliepophttps://x.com/lawliepopDoctor Guest: Dr Komal Patil-Sisodiahttps://www.instagram.com/drpatilsisodia?igsh=MWZyaHY2Mm1naGVwOA%3D%3D&utm_source=qrhttps://www.tiktok.com/@drpatilsisodia?_t=ZT-8zzn5gQRlvy&_r=1https://www.resetrecharge.com/https://www.eastsidemm.com/_______________________________________________________________Send us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

What does it really look like to set realistic expectations with weight loss medications like Zepbound and Wegovy?That's the focus of today's episode, and I'm joined by someone who knows this topic inside and out—Ana Reisdorf, a registered dietitian with over 15 years of experience. Ana is the founder of the GLP-1 Hub, where she provides resources, education, and support for people using GLP-1 medications. She also hosts a podcast dedicated to helping patients navigate the ups and downs of this journey.In our conversation, Ana shares why setting realistic expectations is so important—from understanding how dosing really works, to rethinking nutrition, and even reframing what progress looks like beyond the scale. She also points out common mistakes, like rushing to the highest dose too quickly or overly restricting food, and offers practical guidance on how to avoid them.We talk about:Why balanced nutrition is essential when taking weight loss medicationsWhy the right dose isn't always the highestManaging expectations and comparisons with weight loss medicationsRethinking “responders” and “non-responders” in weight loss medicationsProtein obsession vs. balanced nutritionThe role of fiber and balance in GLP-1 nutritionWhy GLP-1 medications aren't a shortcut—and how to use them effectivelyHow obesity and malnutrition can coexistAt the heart of this conversation is Ana's message that success with GLP-1s isn't just about losing weight—it's about improving health, nourishing the body, and creating a sustainable approach.Catch the full episode for more of Ana's insights and practical advice that can guide your own journey.Connect with Ana:Website: GLP-1 HubFacebook: GLP-1Hub Instagram: glp1hubYoutube:GLP-1 HubConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have become a cultural phenomenon, transforming appetite regulation and weight loss like nothing before. But with their rise comes a flood of imitators, from flashy “GLP-1 patches” to supplements like Calocurb, all promising the same results without the needles or prescriptions. In this episode, I break down what GLP-1 actually is, how these drugs work, and why they're so effective—not just for weight but also for cardiovascular outcomes. Then I take a closer look at the patches (spoiler: marketing magic, not science) and Calocurb's hops extract, which shows some early promise but lacks long-term data. If you're curious about food noise, appetite regulation, and how to separate science from sales tactics, this one's for you.Highlights:How GLP-1 drugs regulate appetite, cravings, and even food noiseWhy “GLP-1 patches” are all marketing and no scienceWhat Calocurb is, how it works, and the research behind itShort-term vs long-term evidence for appetite control Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwillidenSave 20% on all Nuzest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk off your first order

Are compounded GLP-1 meds like semaglutide and tirzepatide a smart shortcut or a risky gamble? In this episode, Dr. Lisa breaks down the real risks, pros & cons, and expert recommendations around using compounded versions of Wegovy, Ozempic, and Zepbound. If you're curious about affordable options for weight loss medications, or wondering if compounded GLP-1s are safe, this episode is for you.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Langtrækkende angreb godkendt af Trump, 'kødfjæset' fra Rusland har tordnet hele weekenden mod Vesten, lad vær med at komme og græde, går-den-så-går-den-doktrinen, Hulubulu – Torsten Boom-Shackalack hvor er du henne? vanvittige dage der udspiller sig i kongeriget Danmark, golde marker og fiberforbundet droneteknik, The Four Amigos til pressemøde, jagerfly på vingerne over Bornholm, transponder-hokus-pokus og kortlægning af rækkevidden på dronerne, Hvem-ved-mest på vejene – og danskerne, #UgensComeback er Syriens nye præsident, Straight to jail med Pedro, Jimmy Kimmel tilbage med rekordseertal, deep dive i podcastmediet, i troede, vi var døde og borte – AGF helt til tops, danskerne prepper på livet løs, Pernille Rosenkrantz-Theil – vi glæder os til, at du sætter dig på posten, hudkorrektioner og indgreb efter Wegovy stiger og alle vil gerne have en genvej til resultaterne.Få 30 dages gratis prøveperiode (kan kun benyttes af nye Podimo-abonnenter)- http://podimo.dk/hgdg (99 kroner herefter)Værter: Esben Bjerre & Peter FalktoftRedigering: PodAmokKlip: PodAmokMusik: Her Går Det GodtInstagram:@hergaardetgodt@Peterfalktoft@Esbenbjerre

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Join us for an eye-opening conversation with Dr. Komal Patil-Sisodia, MD, a board-certified endocrinologist and obesity medicine specialist, as we uncover why healthcare access is so broken for patients seeking GLP-1 treatments and women's health support. From insurance denials to systemic inequities, Dr. Patil-Sisodia breaks down where the system fails—and how it could change for the better. We're also joined by Sabina, founder of GLP Winner, who shares her personal journey with obesity and her mission to help others find reliable information and providers for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.Community Guest: Sabina | https://www.glpwinner.com/ - Helps compare GLP-1 provider options with transparent pricing, sourcing, and reviews.https://www.tiktok.com/@lawliepophttps://www.instagram.com/lawliepops/https://www.youtube.com/@lawliepophttps://x.com/lawliepopDoctor Guest: Dr Komal Patil-Sisodiahttps://www.instagram.com/drpatilsisodia?igsh=MWZyaHY2Mm1naGVwOA%3D%3D&utm_source=qrhttps://www.tiktok.com/@drpatilsisodia?_t=ZT-8zzn5gQRlvy&_r=1https://www.resetrecharge.com/https://www.eastsidemm.com/______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 Send us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Leave Health Bite a Feedback.Click This Link.What if I told you that weight loss drugs like Ozempic, Wegovy, and Mounjaro are not just about shedding pounds—but can also reduce the risk of heart attacks, strokes, and even improve sleep apnea?And what if I also told you that while these medications are powerful tools, they're often misunderstood, misused, and surrounded by myths from self-proclaimed “gurus”?In this episode, Dr. Adrienne Youdim, triple board-certified internist and obesity medicine specialist, breaks down everything you need to know about GLP-1 medications. From how they work, to who should actually use them, to why “compounded” versions can be dangerous—you'll finally get the truth about these drugs and how they fit into the bigger picture of health.Don't forget to share this episode with anyone considering these medications or feeling confused by the hype.What You'll Learn From This Episode:How GLP-1 drugs work: Understand why they're more than “diet drugs” and how they affect appetite, gut function, and blood sugar.Side effects explained: Learn about common gut-related issues, rare but serious risks, and how to minimize discomfort.The truth behind “Ozempic face” and “Ozempic butt”: Why weight loss naturally changes body fat distribution—and why it's not unique to these medications.Who should (and shouldn't) take them: Clear guidelines on BMI, comorbidities, and why these drugs aren't for losing just 5–10 vanity pounds.Why compounding is a red flag: Discover why cheaper compounded versions pose major health risks.What's coming next: From oral GLP-1s to triple agents and even potential uses in conditions like Alzheimer's, alcohol use disorder, and fatty liver disease.“These drugs are powerful—not just for weight loss, but for improving overall health. But they must be used with medical oversight, not as quick fixes from unqualified sellers.” — Dr. Adrienne Youdim3 Ways that Dr. Adrienne Youdim Can Support You Subscribe to Dr. Adrienne's weekly newsletter https://www.dradrienneyoudim.com/newsletter Connect on Instagram : Follow @dradrienneyoudim for tips and inspiration on well-being and peak performance. Come back next week — Every episode of Health Bite explores the physical, emotional, and spiritual hungers that drive us, and delivers the essential “nutrients” you need to thrive.

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

Can body positivity and weight loss medications like Ozempic and WeGovy coexist. Or are they destined to clash? This question has sparked debates across social media and medical offices everywhere. In this episode, I will explore the history of the body positivity movement from its 1960's roots with the National Association to Advance Fat Acceptance to its social media explosion in the 2010's. I will discuss how the movement challenged diet culture and promoted self-love regardless of size. Then, I will also talk about today's weight loss medication revolution and the tension it creates. Some feel that taking these drugs contradicts body positivity principles, while others face judgement for choosing medical intervention. I will address the stigma from both sides, the challenge of redefining health, and how to separate personal choice from cultural pressure. Tune in to discover why these two movements don't have to be at war and how you can find a middle ground of honoring your own health journey without judgment.   Episode Highlights: The history and evolution of body positivity movement How society judges people based on size and the ongoing work needed. The rise of drugs like Zepbound and WeGovy and their health benefits The tension between these two movements seeing it as incompatible to each other's principles. How to embrace both self-acceptance and medical tools for health.   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Is It Too Much in the Name of Health? What if your supplements, workouts, or even recovery methods are secretly working against you? In this episode of The Health Made Simple Show, Dr. Bart dives into three surprising clinical insights that challenge the “more is better” mindset when it comes to health. Tune in to learn: ✔️ Why even the healthiest routines can lead to burnout if you ignore this one mental trap ✔️ What GLP-1 users (Ozempic, Wegovy) must understand about muscle loss and long-term health ✔️ When inflammation is actually good (and why popping anti-inflammatories too soon could sabotage your healing) If you've ever asked yourself: Am I overdoing it in the name of getting healthy?—this one's for you.

GLP-1 medications like Ozempic and Wegovy are making headlines for fast, dramatic weight loss. But here's the uncomfortable question—are we just reliving The Biggest Loser era in injectable form?In this episode, we break down the eerie similarities: short-term success, appetite suppression, rapid weight loss… followed by a return to real life where nothing about your mindset or identity has changed.GLP-1s can be helpful for those facing serious health risks, but if they're not supported by deep, long-term behaviour and belief shifts? The old patterns come back—with interest.If you're on this journey or considering it, this episode is your reality check (minus the shame).

Welcome back, listeners, to Ozempic Weightloss Unlocked. Today, we are uncovering the latest news and updates on Ozempic, from its medical applications to its influence on our daily lives and overall health.There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

This week @littlehannahsucks returns and we start off by discussing her professional ghost of a situation with her fella, posing the question:  Is love for someone with addiction bigger than the love you have for yourself?  @thechrisarmy discusses his journey with Fat Guy Medicine AKA Wegovy. We also discuss the Jimmy Kimmel thing, the weird D4VD case theories and how mmany people have big feelings. Plus where is Josh? You should definitely email  Joshuamann11@gmail.com  and ask him... Please like and subscribe wherever you stream and follow us on YouTube @newbergpod  or watch the show there https://youtu.be/ilwhsGnRrio 

Dr. Fatima Cody Stanford, a leading specialist in obesity medicine and on GLP-1s joins Kelly to answer all of your most pressing questions about weight loss drugs (Ozempic, Wegovy, ZepBound), potential side effects and if it's possible to stop the meds and keep off the weight! She explains why GLP-1s don't work the same for every person, how to manage weight loss related hair loss, and if Ozempic face is a thing. Plus Dr. Stanford breakdowns if GLP-1 boosters are a gimmick. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Celebrate Kids podcast, Dr. Kathy dives into the topic of GLP-1 medications, which have recently gained attention for their use in managing obesity and type 2 diabetes in children and adolescents. She discusses how these injectable drugs, like Wegovy and Victoza, enhance feelings of fullness and reduce appetite to mimick self-control. Dr. Kathy uses this topic to engage how we can teach character, self-control, and have a posture of support for our kids as they face things like obesity and a culture that pushes them to quick-fixes for big problems.

#174  - The Shocking Truth About Ozempic and GLP-1s Your Doctor Won't Tell You with Dr. Jeff Crippen What Your Doctor Isn't Telling You About GLP-1s (And What You Need to Know Before You Fill That Prescription) GLP-1 meds like Ozempic, Wegovy, and Mounjaro have been marketed as magic bullets for weight loss—but there's a whole lot more going on beneath the surface. In this episode, I'm joined by Dr. Jeff Crippen, a chiropractor, naturopath, and creator of the Beyond Ozempic course, to break down what these drugs actually do in your body, how to protect your health while using them—and what your doctor probably didn't mention when handing over the prescription. We talk about: What GLP-1s like Ozempic actually do to your digestion, blood sugar, and muscle mass The real reason so many people regain the weight after stopping the meds The shocking links between GLP-1 use and digestive issues, nutrient deficiencies, and even mental health What you can do to preserve muscle and metabolism while on GLP-1s How to come off them safely—and set yourself up to keep the progress for a lifetime The critical (and completely overlooked) role of stress, trauma, and gut health in sustainable weight loss Plus: why the best long-term fat loss strategy still comes down to very basic but powerful choices If you or someone you love is on a GLP-1 or thinking about it, this episode is required listening. We're pulling back the curtain on what's really happening in your body—and giving you the tools to support it with or without medication.

Dr. Mindy talks about sauerkraut and schnitzel. And then she answers questions about Contrave, autism, the neverending cough, Nugg's sick dumper, Heather's a hippie, swollen lymph nodes, stomach bugs, Wegovy, cold sores and menopause. The Dr. Mindy Experiment on YoutubeSee omnystudio.com/listener for privacy information.

When did Hollywood get so good at cucking? Can hot guys be character actors? Who's your work wife? Would you drink a bucket of Wegovy? And is Shrek real? Plus: Paris Hilton, #MeSlurp, Smooching+ and the Shaquille O'Neal of hiding behind a tree... of braces. Also: Haaaaamburger.Further content:• "I Couldn't Get a Job and I Lost Everything"• "It Had to Be You"• Serena Williams Opens Up About Being on a GLP-1• Subscribe to "Casuals with Katie Nolan" Hosted on Acast. See acast.com/privacy for more information.

In today's episode, I dive into the rising phenomenon of so-called “Ozempic pregnancies” and uncover what's really happening behind the headlines. GLP-1 receptor agonists like Ozempic and Wegovy were originally developed for type 2 diabetes, but are now being used by many women with PCOS, insulin resistance, or weight challenges to support fertility. I'll break down how these medications work, why they may help some women conceive, and the important risks and limitations you need to know. From a Traditional Chinese Medicine (TCM) perspective, we'll explore why simply taking a drug isn't enough to address the root cause, and how digestive health, spleen qi, and lifestyle habits hold the key to lasting fertility and hormone balance. I'll also share practical strategies you can start today, like mindful eating, warming your digestive fire, and syncing with your circadian rhythm, that can naturally support your fertility journey. Key Takeaways:  GLP-1 medications like Ozempic can temporarily improve insulin sensitivity but don't resolve the root causes of infertility. Insulin resistance impacts ovulation, egg quality, and hormone balance, especially in women with PCOS. TCM approaches fertility by strengthening the digestive system and restoring balance, rather than suppressing symptoms. Mindful eating, warm digestion-supporting practices, and aligning meals with the body's circadian rhythm are powerful fertility boosters. Sustainable lifestyle changes are essential for lasting fertility health, beyond short-term medication use. Links mentioned:

Scott Zari says we're in the "very early stages" of the weight loss market. He points to Eli Lilly (LLY) as the market leader but notes Novo Nordisk (NVO) as a strong competitor, especially as it develops a Wegovy pill to compete against Eli Lilly's Zepbound. Scott also touches on Pfizer's (PFE) acquisition of Metsera (MTSR) and called it Pfizer's true way of entering the GLP-1 market after its pill failed.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

A new study shows weight loss drugs like Wegovy and Zepbound don't just help with losing weight they may also protect the heart and save lives. In this episode, we look at a new study that followed over 90,000 people with obesity, type 2 diabetes, and heart failure. The results show that drugs like Wegovy and Zepbound don't just help with weight loss, they can cut the risk of death or hospitalization for heart failure nearly in half. We'll talk about why that matters, how these medications actually work in the body, and what you should know about side effects and access. Most importantly, we'll explore why this research could change how we think about treating obesity not just as a matter of weight, but as a way to save lives. Tune in to the full episode to hear how these weight loss drugs could also protect your heart.   Episode Highlights: The new JAMA study on Wegovy and Zepbound and their impact on heart health. How GLP-1 medications work in the body to lower risk. Why this matters for people with obesity, diabetes, and heart disease. Side effects, diet, and exercise considerations when using these drugs. Challenges with access and cost of these medications.   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Step into the “Skinny Games” with Dr. Sofia Din, a board-certified longevity doctor in New York.

Friday, September 19. The seven stories you need to know today.Read today's briefing.If you're not a subscriber, click here to start.

GLP-1 medications like Ozempic®, Wegovy®, or Mounjaro® can be powerful tools for appetite control and weight loss-but here's the truth no one's talking about: without strength training, you risk losing valuable muscle right along with the fat.In this episode, I break down why lifting weights is non-negotiable for women over 40 using GLP-1s. You'll learn:The science behind how these medications impact your body.The hidden danger of muscle loss and slowed metabolism.How strength training protects your long-term health, bone density, and fat loss results.Exactly what kind of workouts women should focus on to stay strong, energized, and confident.If you're ready to move beyond the scale and truly transform your body, this episode is your guide.Join us in the Inspire Fitness program: Use the link here: https://inspirehw.com/ Follow me on Instagram: https://www.instagram.com/fit.nutritionist?igsh=MTJqZXhjODR2ZzduaA%3D%3D&utm_source=qr Follow me on Facebook: https://www.facebook.com/Casey.Young.RD.CPT?mibextid=LQQJ4d

A.M. Edition for Sept. 18. The entertainment giant is pulling ‘Jimmy Kimmel Live!' after Kimmel accused ‘MAGA-land' figures of exploiting Kirk's death, sparking outrage from conservatives. Plus, the WSJ's Peter Loftus explains how weight-loss pills are going to upend the market, as a Novo Nordisk trial shows the pill is just as effective as its Wegovy shot. And, royalty, lavish dinners and tech CEOs: Britain turns on the charm offensive as Donald Trump's state visit to the United Kingdom continues. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: We're exclusively reporting that Pentagon lawyers are raising concerns over President Trump's strikes on alleged drug boats. And, Novo Nordisk says its daily WeGovy pill helps patients lose about as much weight as its weekly injection. Kate Bullivant hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Weight loss medications are big pharma's golden goose, expectedto sell nearly $140 billion per year in 2030. But are they safe, or just profitable? There's a lot of mixed informatin out there around these drugs, so I looked at the research and in this episode, I give you both sides so you can make a decision for yourself.   TOPICS DISCUSSED: The history of GLP-1 medications What they were used for vs. what we use them for today How they work and what they do in your body The pros and cons of these medications Risks associated with them Stores from those who have tried using them Reviewing the medical literature    Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Visit my website gutsolution.ca to join a program: Get help now   Contact us: reversablepod.com/tips    FIND ME ON SOCIAL MEDIA: Instagram  Facebook  YouTube

So… Serena Williams shares she used GLP-1s to support her weight loss and the internet implodes with hot takes, shade, and side-eyes. Here's the truth: when it comes to midlife weight loss, some folks don't come to this decision lightly, and others are judging from the sidelines. If you've ever felt like you had to hide what's working for you because someone else might label it "cheating," this Fit Girl Magic podcast episode is your permission slip to shut that noise down. In this candid, smart, and hilarious conversation, I sat down with Dr. Megan Garcia Webb, triple board-certified in internal medicine and obesity medicine (yes, triple), to break down:   ·      What GLP-1s like Ozempic, Wegovy, and Zepbound actually do ·      Why “food noise” might be what's really driving your cravings ·      The real deal on side effects like muscle loss, gut issues, and does it really cause cancer ·      Who's a great candidate for these meds, and who should pause before jumping in ·      Why natural GLP boosters are more boring than sexy (but still matter) ·      How social media makes women feel like they're doing it “wrong”, no matter what they choose ·      The #1 most underrated weight loss tool (spoiler: it's not a supplement) ·      Whether you're GLP-curious, already on it, or side-eyeing it from afar, this episode is about giving you clarity, facts, and a whole lot of freedom. DM me or tag us if something in this conversation made you say, “Wait… I never thought of it like that!” Links + Resources: Dr. Megan Garcia Webb's website: YouTube channel: Previous Ozempic podcast Everything You Need to Know About Ozempic with Dr. Janese Lester    Facebook group Free Resources: https://www.fitgirlmagic.com/freeresources_podcast Website:  http://www.kimbarnesjefferson.com  FREE Challenge 5 Days To Break The All Or Nothing Instagram https://www.instagram.com/kimjeffersoncoach

In this podcast, Stephen Martin shares his personal journey with weight loss and health, focusing on the interplay between the keto diet, Vyvanse, and Wigovy. He discusses his experiences with these methods, the challenges he faces, and the strategies he employs to maintain his health and achieve his weight loss goals. The conversation emphasizes the importance of understanding how different dietary approaches can work together, especially for individuals with ADHD and other cognitive differences.TakeawaysVyvanse helps keep focus and reduces food cravings.Keto can be adapted to include higher protein and lower fat.Wigovy has shown potential in managing hunger and fullness.Combining different dietary strategies can enhance weight loss efforts.Electrolytes are crucial when following a keto diet.Personal experiences with weight loss can vary significantly.Maintaining a balanced approach is key to long-term success.Using food for dopamine can be a challenge for many.Trial and error is part of finding what works best for you.Staying committed to health goals requires ongoing effort and adjustment.Vyvanse, Wigovy, Keto, weight loss, ADHD, health, nutrition, personal journey, dietary strategies, mental health, adults with dyslexia, support for adults.Join the club⁠rightbrainresetters.com⁠Get 20% off your first order⁠addednutrition.com⁠If you want to find out more visit:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠truthaboutdyslexia.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join our Facebook Group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠facebook.com/groups/adultdyslexia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Comedians Te Radar and Pinky discuss a worm charming championship, restaurants catering for people wanting to eat less thanks to drugs like Wegovy, and the Christchurch mum who broke the running-barefoot-on-lego record.

Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 18 septembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

GLP-1 has been making headlines thanks to weight loss medications like Ozempic and Wegovy—but here's the thing: your body already makes GLP-1 naturally. This powerful gut hormone plays a key role in satiety, blood sugar balance, and metabolic health.In this episode, I break down:What GLP-1 is and how your body makes itThe foods and lifestyle habits that naturally support GLP-1 productionThe fascinating role of gut bacteria—like Akkermansia muciniphila and Clostridium butyricum—in lowering inflammation and improving metabolic functionMetabolic daily probiotic linked in my FullscriptWhy GLP-1 is about more than just weight loss, and how it ties into energy, digestion, and long-term healthIf you've been curious about natural ways to support your metabolism, gut health, and energy (without chasing quick fixes), this episode will give you practical, root-cause strategies you can start using today.✨ Takeaway: You don't need to rely on injections—your body is designed to make GLP-1 when you give it the right inputs.

We are finally talking about GLP-1s! GLP-1 meds like Ozempic and Wegovy are everywhere right now… and if you're curious, confused or concerned about them - I don't blame you. And today, we're demystifying it. I'm sitting down with licensed psychotherapist,  best-selling author, mind-body practitioner, and trauma-informed weight-management specialist, Eliza Kingsford. We're unpacking the truth about GLP-1s - how they actually work in the body, what the research is showing, and the surprising ways they affect food cravings, appetite, and even our brain's reward system.This isn't your typical black-and-white “these drugs are good or bad” kind of talk. Eliza and I go deeper and unpack:What's really happening in your body when you're on GLP-1s (hint: it's not the drug itself causing weight loss). The surprising side effects no one really talks about  Why taking the meds without focusing on protein, muscle, and movement can actually backfire. How these drugs intersect with eating disorders, body image, and self-worth. Why a holistic approach is the only way to create freedom that actually lasts.At the end of the day, this episode is about cutting through the noise and giving you the nuance and truth so you can make the best decision for your health, your body, and your peace of mind.Connect with Eliza:Website: elizakingsford.comInstagram: @elizakingsfordFree Guide: The Ultimate Gide To Navigating GLP-1 Medications For Weight Loss

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

In this episode, Shana Hussin, RDN, shares the replay of her recent webinar on GLP-1 — the hormone behind today's most popular weight loss drugs like Ozempic, Wegovy, and Mounjaro. You'll learn: ✔️ What GLP-1 is and how it works in the body ✔️ Natural ways to increase GLP-1 for fewer cravings, better blood sugar, and fat loss ✔️ Lifestyle habits that decrease GLP-1 and fuel insulin resistance ✔️ The truth about GLP-1 medications: cost, side effects, and sustainability ✔️ How to safely transition off GLP-1 drugs by improving natural GLP-1 and gut health ✔️ The research behind Unimate Yerba Mate and Balance Fiber Matrix — and how they support GLP-1 signaling in the Feel Great System ✨ If you've ever wondered whether you really need expensive GLP-1 medications, or if there's a more sustainable, root-cause solution, this episode is for you. Resources & Links:

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Send us a textWe've all heard about the dramatic weight-loss results from drugs like Ozempic®, Wegovy®, semaglutide, and tirzepatide, but what aren't you hearing about? In this episode of The Trillium Show, board-certified plastic surgeon Dr. Jason Hall explains the under-the-radar effects these GLP-1 medications can have on your face and skin, including accelerated volume loss, thinning, and changes to your skin's ability to rejuvenate itself.Dr. Hall breaks down:Why these drugs can dramatically change your skin qualityWhat treatments (fat transfer, fillers, lasers, etc.) may help combat this and their limitationsHow to protect your muscle mass and skin health if you're taking or considering GLP-1sIf you're curious about the real impact of GLP-1 medications on aging skin, this episode is a must-listen.

Hoy tenemos Consultorio con el Dr. Fernando Pérez Galaz, Médico cirujano especialista en cirugía del aparato digestivo y cirugía bariátrica, y nos va a responder todas las dudas sobre los GLP-1, es decir el Ozempic, Wegovy, Mounjaro y otras marcas más. Hosted on Acast. See acast.com/privacy for more information.

In her annual State of the Union address, European Commission president Ursula von der Leyen has told the European Parliament it needs to regain its independence and bolster its defence capabilities in a 'hostile' world. Also, Danish company Novo Nordisk, the maker of weight-loss drugs Wegovy and Ozempic, has announced plans to cut 9,000 jobs. And the British horse racing industry has gone on strike for the first time ever, in protest at proposed tax rises on bets placed on the sport. You can contact us on WhatsApp or send us a voicenote: +44 330 678 3033.

If you've been hearing all the buzz about GLP-1 medications like Ozempic, Wegovy, or Zepbound, and you're wondering if they could be the right fit for you at midlife, this is the episode to press play on. We brought on nurse practitioner and health optimization expert Amy Wrenn to demystify what GLP-1s actually are, how they work, who they're for, and what you really need to know about taking them during perimenopause and menopause. Amy is passionate, informed, and totally relatable—she cuts through the hype to bring clarity to a topic that's been wrapped in confusion and judgment.In this conversation, we get real about our own experiences, bust some myths, talk side effects (yep, we go there), and explore the broader context of hormone therapy, weight gain, metabolic dysfunction, and the importance of doing what works for your individual body and life. Whether you're curious, cautious, or already on a GLP-1, this is a must-listen packed with valuable insights.  Episode Highlights:[0:00] - Welcoming Amy Wrenn and kicking off our deep dive into GLP-1s [3:10] - What exactly are GLP-1s, and how do they work in your body? [5:00] - Understanding insulin resistance, perimenopause, and why midlife changes everything [6:57] - Real-life examples of "metabolic mayhem" that hits out of nowhere [8:03] - Challenging the lazy stereotype: GLP-1s are not a quick fix [10:08] - The far-reaching benefits: inflammation, PCOS, cognitive health, and more [12:10] - Social media hype vs. safe medical prescribing—know the difference [13:46] - Compounded medications vs. name-brand prescriptions: what to watch for [17:33] - Who qualifies for GLP-1s, and what do providers look for? [20:43] - It's not about skinny—it's about healthy: the real goal of treatment [22:34] - Common side effects: what to expect and how to manage them [25:25] - Nutrition matters: prioritizing protein, avoiding high-fat traps [26:38] - Surprising benefits: reduced alcohol cravings, better food boundaries [28:12] - Coming off GLP-1s: what it looks like, and when it's okay to stay on [31:48] - Does your body adapt over time? Amy explains habituation and dosing [33:32] - The power trio: GLP-1s, HRT, and resistance training [36:08] - Hormone therapy explained: symptom relief vs. long-term prevention [40:51] - Why we're not getting this info from our doctors—and how to change that [42:24] - Where to follow Amy and keep learning more  Links & ResourcesFollow Amy Wrenn, NP on Instagram: https://www.instagram.com/np_wrenn If today's discussion resonated with you or sparked curiosity, please rate, follow, and share "Insights from the Couch" with others. Your support helps us reach more people and continue providing valuable insights. Here's to finding our purposes and living a life full of meaning and joy. Stay tuned for more!Come hang out with us in The Chat, our free community for midlife women, where we keep theconversation going at insightsfromthecouch.org/the-chat. And don't forget todownload our free guide 7 Skills to Master Midlife so you can stop living small, start taking action, andlive the life you really want at insightsfromthecouch.org/midlife-roadmap.

This week on Two Parents & A Podcast, we're joined by Dr. Stephanie Culler — a microbiome scientist and baby gut health expert — to talk about one of the most important (and overlooked (like seriously we had no clue!!!)) parts of raising healthy kids: the gut. Dr. Culler breaks down what gut health actually is, why so many babies are born missing critical microbes, and what that means for things like chronic illness, food allergies, eczema, and even obesity later in life. Dr. Culler shares what parents can do in the first 1,000 days (from pregnancy through toddlerhood) to set their child up for lifelong health, from everyday food choices to the role of antibiotics, and how her groundbreaking study revealed that most babies around the world lack the microbes they need. We also get into practical solutions — like how parents can help restore those microbes through Persephone's new infant & toddler synbiotic (or any pre/probiotic!!!) — plus the foods to focus on (and avoid), and why gut health should be part of every child's standard care. If you're curious about how to give your baby the healthiest start possible, this one's packed with insights you won't want to miss. LOVE YOU GUYS! Timestamps: 00:00:00 Welcome back to Two Parents & A Podcast!  00:02:07 Meet Dr. Stephanie Culler (Microbiome Scientist) 00:03:05 What is gut health—and why it matters for families  00:06:30 The current state of kids' health in the U.S.— chronic illness, food allergies, eczema & obesity  00:10:50 The #1 thing parents can do to help kids live healthier lives  00:13:58 My Baby Biome study reveals a shocking global trend: most babies lack key gut microbes for lifelong health  00:19:34 How do we get babies this bacteria back? Introducing Persephone's infant & toddler synbiotic  00:29:00 Building a better baby gut: recommended foods & foods to avoid  00:33:00 How antibiotics affect gut health in babies & kids (as early as during pregnancy) 00:38:00 Just how important is gut health for kids?—and making it standard of care  00:41:48 LOVE YOU GUYS!  #twoparentsandapod --------------------------------------------------------------- Thank you to our sponsors this week: *OneSkin: Get 15% off OneSkin with the code TWOPARENTS at https://www.oneskin.co/  #oneskinpod *Hers: Start your initial free online visit today at https://www.forhers.com/ALEX for your personalized weight loss treatment options. Hers Weight Loss is not available everywhere. Compounded products are not FDA-approved or verified for safety, effectiveness, or quality. Prescription required. Restrictions apply. Wegovy® and Ozempic® are not compounded. Actual price depends on product and plan purchased. --------------------------------------------------------------- Listen to the pod on YouTube/Spotify/Apple: https://www.youtube.com/@twoparentsandapod https://open.spotify.com/show/7BxuZnHmNzOX9MdnzyU4bD?si=5e715ebaf9014fac https://podcasts.apple.com/us/podcast/two-parents-a-podcast/id1737442386 --------------------------------------------------------------- Follow Two Parents & A Podcast: Instagram | https://www.instagram.com/twoparentsandapod TikTok | https://www.tiktok.com/@twoparentsandapod Follow Alex Bennett: Instagram | https://www.instagram.com/justalexbennett TikTok | https://www.tiktok.com/@justalexbennett Follow Harrison Fugman: Instagram | https://www.instagram.com/harrisonfugman TikTok | https://www.tiktok.com/@harrisonfugman Find our guest: Website | https://www.persephone.bio/ Instagram | https://www.instagram.com/persephone.bio TikTok | https://www.tiktok.com/@persephone.bio --------------------------------------------------------------- Powered by: Just Media House – https://www.justmediahouse.com/ --------------------------------------------------------------- Learn more about your ad choices. Visit megaphone.fm/adchoices

Freeform reveals lineup for '31 Nights of Halloween'; New study on Wegovy and heart disease; Lauren Roberts talks new book, 'Fearful' Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: The 3-Step "SBC" Weight-Loss Framework That Works Every Time. (1:48) Ways to safeguard yourself from developing dementia. (23:16) An update on Sal's Journey in Faith & Fitness. (29:50) Methylene Blue's cognitive benefits. (35:21) The little-sibling effect on athleticism. (39:45) Men's skincare market is blowing up! (45:12) The Caltrans “party.” (51:33) #ListenerLive question #1 – Any advice on why my InBody scan showed my body fat went up 6% in a span of 7 months? (56:01) #ListenerLive question #2 –  Is it reasonable to expect a 100-pound jump on my deadlift in a year? (1:07:05) #ListenerLive question #3 – What are some neat, effective, and portable equipment options I should consider having available for my mobile training sessions? Additionally, do you have any business advice or tips for someone making this transition to a mobile personal training model? (1:16:31) #ListenerLive question #4 – What's the best way to support muscle growth and prevent muscle loss while using GLP-1, especially with appetite suppression? What mental shifts do you recommend when transitioning from years of dieting into a performance and strength-driven mindset? (1:25:52) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Troscriptions for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP for 10% off your first order. ** Visit Caldera Lab for an exclusive offer for Mind Pump listeners! **Code MINDPUMP20 for 20% off your first order of their best products. ** August Special: MAPS 15 50% off! ** Code MUSCLE50 at checkout ** Mind Pump #2552: From Plateau to PR… How to Break Through Strength Barriers Mind Pump #2372: Five Steps to a Faster Metabolism Mind Pump #2450: The Smartest Way to Use Protein to Burn Fat & Build Muscle Mind Pump #2287: Bodybuilding 101- How to Bulk and Cut Physically Fit Women Were Less Likely to Develop Dementia, Study Says Sal Di Stefano's Journey in Faith & Fitness – Mind Pump TV Methylene Blue Shows Promise for Improving Short-Term Memory How To Be An Elite Athlete, According To The Data - NPR Caltrans investigates Monterey on-duty party with alcohol, stripper; 10 face firing Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** Mind Pump #2566: The Best Way to Measure Progress in the Gym & More (Listener Live Coaching) Mind Pump #1962: How to Hit a Deadlift PR in 30 Days Mind Pump Personal Training – Apply today! Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Building Muscle with Adam Schafer – Mind Pump TV Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned IFBB PRO Johnny Sebastian (@_johnnysebastian) Instagram Denis Roberts (@denis_kokushi) Instagram Dr. John Delony (@johndelony) Instagram

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy